Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 4/20 | 0.43 |
| ▸ | PLAU | P00749 | 3/20 | 0.43 |
| ▸ | F2 | P00734 | 2/20 | 0.43 |
| ▸ | HTR3A | P46098 | 7/20 | 0.41 |
| ▸ | REN | P00797 | 4/20 | 0.39 |
| ▸ | CNR1 | P21554 | 4/20 | 0.37 |
| ▸ | CNR2 | P34972 | 4/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4291159 | 0.99 | ELANE (0.43) | ELANEPLAUF2HTR3AREN | |
| SCHEMBL4303724 | 0.83 | KDM4E (0.36) | REN | |
| Hydrochloric Acid SCHEMBL4290890 | 0.82 | KDM4E (0.38) | REN | |
| SCHEMBL4292396 | 0.82 | ELANE (0.44) | ELANEPLAUF2HTR3ACNR1 | |
| SCHEMBL4289440 | 0.81 | CYP11B2 (0.37) | REN | |
| SCHEMBL4287498 | 0.74 | EGLN3 (0.50) | — | |
| SCHEMBL4290999 | 0.74 | KMO (0.50) | REN | |
| SCHEMBL4753442 | 0.74 | KMO (0.50) | REN | |
| Hydrochloric Acid SCHEMBL4281468 | 0.74 | REN (0.33) | REN | |
| SCHEMBL31429235 | 0.73 | ELANE (0.57) | ELANEPLAUF2HTR3ACNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227560-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227560-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | ELANE 573/4885PLAU 866/4885F2 1920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.